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Background: DNA methylation is strongly associated with smoking status at multiple sites across the genome.
Studies have largely been restricted to European origin individuals yet the greatest increase in smoking is occurring
in low income countries, such as the Indian subcontinent. We determined whether there are differences between
South Asians and Europeans in smoking related loci, and if a smoking score, combining all smoking related DNA
methylation scores, could differentiate smokers from non-smokers.
Results: Illumina HM450k BeadChip arrays were performed on 192 samples from the Southall And Brent REvisited
(SABRE) cohort. Differential methylation in smokers was identified in 29 individual CpG sites at 18 unique loci.
Interaction between smoking status and ethnic group was identified at the AHRR locus. Ethnic differences in DNA
methylation were identified in non-smokers at two further loci, 6p21.33 and GNG12. With the exception of GFI1 and
MYO1G these differences were largely unaffected by adjustment for cell composition. A smoking score based on
methylation profile was constructed. Current smokers were identified with 100% sensitivity and 97% specificity in
Europeans and with 80% sensitivity and 95% specificity in South Asians.
Conclusions: Differences in ethnic groups were identified in both single CpG sites and combined smoking score.
The smoking score is a valuable tool for identification of true current smoking behaviour. Explanations for ethnic
differences in DNA methylation in association with smoking may provide valuable clues to disease pathways.
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Smoking associated death and disability remains a major
public health problem in high income countries, despite
marked declines in smoking rates, and is escalating
rapidly in low to middle income countries, where
tobacco consumption is increasing [1]. While global
smoking cessation is the ultimate goal, understanding the
mechanisms by which smoking causes its adverse effects
in the interim may provide valuable therapeutic targets.
Smoking is an exposure strongly associated with DNA
methylation in a distinct set of loci which not only clearly
distinguish between current and never smokers, but may* Correspondence: hannah.elliott@bristol.ac.uk
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unless otherwise stated.also reflect the cumulative amount smoked, and time
since quitting in former smokers [2-8]. Some of these loci
are located in characterised genes where the potential
molecular pathway in response to smoking is relatively well
understood, such as the AHRR gene [9,10]. Methylation at
smoking associated loci has also been related to clinical
outcomes; for example, F2RL3 methylation is strongly
associated with mortality in coronary heart disease patients
[11] and AHRR methylation has been investigated in lung
cancer patients [6].
Previous research has almost exclusively been performed
in European origin populations, and may not extrapolate
to other ethnic groups, such as South Asians, where
escalating rates of tobacco consumption will impact
adversely on an already elevated susceptibility to
cardio-metabolic disease [12]. We and others reporttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 SABRE cohort characteristics
Europeans South
Asians
P-valuea
Never smokers
N 65 64
Age in years, mean (SD) 48.5 (4.6) 48.3 (4.3) 0.74
Former smokers
N 14 10
Age in years, mean (SD) 47.9 (4.2) 46.6 (4.4) 0.46
Age started smoking in years,
mean (SD)
17.9 (3.6) 21.5 (6.5) 0.18
Number of cigarettes smoked/day,
mean (SD)
23 (12) 13 (9) 2.5 × 10-2
Pack years, mean (SD) 19.9 (14.0) 10.5 (9.9) 8.1 × 10-2
Time since quitting in years,
mean (SD)
12.9 (7.9) 12.1 (8.0) 0.82
Current smokers
N 16 20
Age in years, mean (SD) 46.9 (3.9) 47.8 (4.3) 0.53
Age started smoking in years,
mean (SD)
17.9 (4.8) 22.3 (5.8) 2.2 × 10-2
Number of cigarettes smoked/day,
mean (SD)
23 (9) 13 (6) 1.0 × 10-3
Pack years, mean (SD) 34.8 (19.3) 17.8 (9.9) 4.5 × 10-3
at-test for ethnic group differences.
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Europeans [13,14], though whether these are associated
with smoking behaviour is unknown. Potential ethnic
differences may be due to different smoking behaviours, or
differences in molecular mechanisms which are important
to identify and explore.
Our primary aim was therefore to determine whether
there are differences in DNA methylation patterns in
association with smoking between people of South Asian
and European origin and to explore whether any differences
observed could be explained by ethnic specific smoking
behaviours. This was carried out using the Illumina
HumanMethylation450 BeadChip array in samples from
the Southall And Brent REvisited (SABRE) cohort.
Secondly, we explored the potential use of a recently
published epigenome-wide catalogue of smoking related
methylation loci to characterise smoking behaviour in
this bi-ethnic sample using a scoring method based on
methylation data [7]. Methylation derived scores
have previously been used successfully using bisulphite
pyrosequencing data to identify former smokers [8]. These
methods could potentially replace and/or provide greater
precision to self-reported smoking habits where
under-reporting is commonplace [15,16] and where
measuring smoking via other methods (for example,
by plasma or salivary cotinine) may be difficult or less
informative, for example, when attempting to quantify
historical behaviours.
Results and discussion
Smoking behaviour in the SABRE cohort
By design, mean age and proportions of men in different
smoking categories did not differ by ethnicity (Table 1).
European current smokers smoked more heavily per day,
started smoking earlier and therefore had a greater number
of pack years smoked than South Asians. However, time
since cessation of smoking for former smokers was similar
by ethnic group (see Table 1 for test statistics).
Smoking associated loci in the SABRE cohort
Differential methylation in current smokers was identified
in 29 individual CpG sites at 18 unique loci at P ≤1.1 × 10-7
after applying conservative family wise error rate correction
based on the number of tests conducted and α = 0.05
(Figure 1). At 12 loci, the effect size (calculated as
median % methylation difference) was greater than
5% (Table 2, summary and test statistics for all CpG
sites in Additional file 1). At each locus, the sentinel
methylation site was defined as the locus CpG site
with the smallest P-value test statistic.
The highest ranking hit was the AHRR locus, with a
median decrease in methylation of 22% in smokers,
confirming both the locus and magnitude of effect
observed in previous studies. Other loci identified(GNG12, GFI1, ALPPL2, 3p24.3, PDZD2, 6p21.33,
VARS, MYO1G, C14orf43, F2RL3) were also concordant
with published data [4,6,7]. The 11th ranked locus, within
TMEM51 (cg09069072) with a decrease in methylation in
current smokers of 6%, has been identified in just
one previous study [7].
The majority of smoking associated loci appeared to be
robust to adjustment for cell composition within samples
(see Additional file 1 for test statistics). Notable exceptions
included GFI1 and MYO1G. In initial analysis of GFI1, the
median methylation level was 27% in smokers and 57% in
never smokers (F = 47.85, P = 1.0 × 10-10). Following cell
composition adjustment, the median methylation level
was 45% in smokers and 58% in never smokers (F = 0.35,
P = 5.6 × 10-1). In initial analysis of MYO1G, the median
methylation level was 95% in smokers and 83% in never
smokers (F = 89.85, P = 3.1 × 10-17), while following cell
composition adjustment the median methylation level was
86% in both smokers and never smokers (F = 23.18,
P = 3.4 × 10-6). The results for these loci may therefore be
a consequence of smoking-related changes in leukocyte
number, differentials and/or inflammatory mediators [17].
Association between methylation and detailed
characterisation of smoking behaviour
When testing the association between number of cigarettes
smoked per day or pack years with methylation at each
Figure 1 Manhattan plot showing association between current and never tobacco smoking and genome-wide DNA methylation. The
continuous line marks the P ≤1.1 × 10-7 significance threshold. CpG sites with corresponding P-values at ≤1.1 × 10-7 are colour coded to show the
direction of difference between smokers and non-smokers. Red CpG sites are hypermethylated in current smokers while blue CpG sites
are hypomethylated.
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cg06126421, was associated with number of cigarettes
smoked per day in current smokers (0.058 unit decrease
in methylation M-value per additional cigarette smoked
per day (95% CI: -0.094, -0.022; P = 2.0 × 10-03)) or pack
years (0.034 unit decrease in methylation M-value per
additional pack year smoked (95% CI: -0.054, -0.015;
P = 1.0 × 10-03)). No CpG sites were associated with
age at which an individual started or quit smoking
after adjusting for multiple testing.
Ethnic differences: interaction
In order to assess differences across ethnic groups,
analyses were initially performed across all CpG sitesTable 2 Summary and test statistics for the 12 sentinel CpG s
Target ID Chr Location
(bp)a
Gene ID or
region
Relation to
CpG island
Median β-va
Never smok
cg09069072 1 15482753 TMEM51 South Shore 0.85 (0.82, 0.8
cg25189904 1 68299493 GNG12 South Shore 0.25 (0.20, 0.3
cg09935388 1 92947588 GFI1 CpG Island 0.57 (0.42, 0.7
cg21566642 2 233284661 2q37.1 CpG Island 0.49 (0.43, 0.5
cg03274391 3 22413232 3p24.3 North Shore 0.31 (0.21, 0.4
cg05575921 5 373378 AHRR North Shore 0.77 (0.74, 0.7
cg13039251 5 32018601 PDZD2 0.71 (0.65, 0.7
cg06126421 6 30720080 6p21.33 0.75 (0.64, 0.8
cg17619755 6 31760629 VARS North Shelf 0.61 (0.57, 0.6
cg22132788 7 45002486 MYO1G CpG Island 0.83 (0.76, 0.8
cg01731783 14 74211788 C14orf43 0.40 (0.35, 0.4
cg03636183 19 17000585 F2RL3 North Shore 0.36 (0.31, 0.4
alocation based on build37/hg19 reference assembly. bEffect size is calculated as th
of difference is indicated by +/−. cF-statistic and P-values from ANOVA measuring astratified by ethnic group. Although no additional loci
were identified following this analysis, differences in effect
sizes at the 12 sentinel CpG sites were observed between
the two ethnic groups. Summary and test statistics for
sentinel CpG sites stratified by ethnic group are shown in
Table 3 and Additional file 1, including analyses adjusting
for cell composition. Ethnic differences in the associations
between smoking and methylation at the 12 sentinel CpG
sites were therefore assessed further.
An interaction between ethnic group and smoking
status was observed in AHRR CpG site cg05575921 after
applying a conservative family-wise error rate correction for
12 tests at α = 0.05 (P ≤0.004) (F = 10.42, P = 1.0 × 10-3). No
ethnic differences in methylation were observed betweenites comparing never with current smokers
lues (IQR) all samples Effect size
(%)b
F-statisticc P-valuec Rank
ers Current smokers
7) 0.79 (0.75, 0.83) −0.06 31.49 8.5 × 10-8 11
2) 0.18 (0.16, 0.22) −0.07 35.05 1.9 × 10-8 7
5) 0.27 (0.21, 0.38) −0.30 47.85 1.0 × 10-10 6
2) 0.32 (0.28, 0.37) −0.16 172.13 3.0 × 10-27 2
4) 0.56 (0.34, 0.75) +0.25 34.56 2.3 × 10-8 8
9) 0.55 (0.52, 0.58) −0.22 658.31 6.1 × 10-59 1
9) 0.83 (0.76, 0.89) +0.11 33.46 3.7 × 10-8 9
2) 0.52 (0.41, 0.66) −0.23 63.64 2.6 × 10-13 5
5) 0.67 (0.63, 0.72) +0.05 31.89 7.2 × 10-8 10
9) 0.95 (0.90, 0.97) +0.12 89.85 3.1 × 10-17 4
3) 0.33 (0.31, 0.37) −0.07 31.46 8.6 × 10-8 12
0) 0.23 (0.20, 0.28) −0.12 93.30 1.0 × 10-17 3
e median methylation difference between smokers and non-smokers. Direction
ssociation between smoking status and methylation adjusted for ethnic group.
Table 3 Sentinel CpG site summary and test statistics comparing never with current smokers, stratified by ethnicity
Target ID Chr Location
(bp)a
Gene ID or
region
Median β-values (IQR) European Effect size
(%)b
F-statisticc P-valuec Median β-values (IQR) South Asian Effect size
(%)b
F-statisticc P-valuec
Never smokers Current smokers Never smokers Current smokers
cg09069072 1 15482753 TMEM51 0.86 (0.82, 0.88) 0.80 (0.76, 0.83) −0.06 13.44 4.5 × 10-4 0.84 (0.82, 0.87) 0.79 (0.74, 0.83) −0.05 17.82 6.2 × 10-5
cg25189904 1 68299493 GNG12 0.23 (0.19, 0.29) 0.16 (0.14, 0.17) −0.07 28.75 8.0 × 10-7 0.28 (0.21, 0.34) 0.21 (0.18, 0.24) −0.06 11.27 1.2 × 10-3
cg09935388 1 92947588 GFI1 0.54 (0.39, 0.76) 0.21 (0.20, 0.27) −0.33 32.92 1.7 × 10-7 0.58 (0.43, 0.74) 0.34 (0.26, 0.45) −0.24 17.07 8.6 × 10-5
cg21566642 2 233284661 2q37.1 0.49 (0.46, 0.53) 0.31 (0.28, 0.33) −0.18 140.33 3.4 × 10-19 0.46 (0.39, 0.50) 0.35 (0.28, 0.37) −0.12 57.96 4.1 × 10-11
cg03274391 3 22413232 3p24.3 0.30 (0.21, 0.45) 0.66 (0.53, 0.77) 0.36 40.10 1.4 × 10-8 0.33 (0.22, 0.44) 0.36 (0.27, 0.70) 0.03 6.05 1.6 × 10-2
cg05575921 5 373378 AHRR 0.77 (0.74, 0.79) 0.53 (0.50, 0.55) −0.24 413.13 4.1 × 10-33 0.77 (0.74, 0.79) 0.57 (0.53, 0.62) −0.19 295.15 6.7 × 10-29
cg13039251 5 32018601 PDZD2 0.72 (0.65, 0.80) 0.84 (0.77, 0.90) 0.12 16.88 9.7 × 10-5 0.71 (0.66, 0.79) 0.79 (0.74, 0.88) 0.08 17.00 8.9 × 10-5
cg06126421 6 30720080 6p21.33 0.72 (0.59, 0.78) 0.42 (0.38, 0.48) −0.30 48.71 8.2 × 10-10 0.78 (0.68, 0.87) 0.65 (0.53, 0.71) −0.14 21.23 1.5 × 10-5
cg17619755 6 31760629 VARS 0.61 (0.56, 0.65) 0.71 (0.63, 0.72) 0.10 22.31 9.9 × 10-6 0.62 (0.58, 0.67) 0.66 (0.64, 0.72) 0.04 11.07 1.3 × 10-3
cg22132788 7 45002486 MYO1G 0.81 (0.76, 0.88) 0.96 (0.94, 0.97) 0.15 84.27 4.3 × 10-14 0.84 (0.77, 0.90) 0.91 (0.87, 0.96) 0.07 24.83 3.4 × 10-6
cg01731783 14 74211788 C14orf43 0.41 (0.35, 0.44) 0.33 (0.31, 0.37) −0.08 97.05 2.1 × 10-15 0.40 (0.35, 0.42) 0.32 (0.30, 0.38) −0.08 16.28 1.2 × 10-4
cg03636183 19 17000585 F2RL3 0.36 (0.31, 0.39) 0.22 (0.19, 0.23) −0.14 15.30 1.9 × 10-4 0.35 (0.32, 0.42) 0.27 (0.24, 0.30) −0.08 24.68 3.6 × 10-6
aLocation based on build37/hg19 reference assembly. bEffect size is calculated as the median methylation difference between smokers and non-smokers. Direction of difference is indicated by +/−. cF-statistic and
P-values from ANOVA measuring association between smoking status and methylation in the ethnic sub-group.
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http://www.clinicalepigeneticsjournal.com/content/6/1/4never smokers at this CpG site (t-test: n = 129, P = 0.44).
Among current smokers the median methylation level was
53% in Europeans and 57% in South Asians (t-test: n = 36,
P = 2.0 × 10-3) (Figure 2).
Heavier smoking in Europeans could account for
their lower methylation scores. However, there was
no relationship between methylation at the AHRR
sentinel CpG site and pack years smoked (unadjusted
linear regression, 0.004 unit decrease in methylation
M-value per additional pack year smoked (95% CI: -0.010,
0.003; P = 0.24)) or number of cigarettes smoked per day
(unadjusted linear regression, 0.006 unit decrease in
methylation M-value per additional cigarette smoked per
day (95% CI: -0.017, 0.006; P = 0.34)). Adjusting for the
number of cigarettes smoked per day in the model did not
change the estimate or P-value, indicating that measured
smoking behaviour could not account for our observed
ethnic differences in methylation. However, there may be
other measures of smoking heaviness; for example, the
brand of cigarette smoked and degree of inhalation,
which we did not capture, which may contribute to ethnic
differences in methylation score.
In other non-sentinel AHRR CpG sites for which
differential methylation with smoking was observed
(n = 8), two further CpG sites also showed an interaction
between ethnic group and smoking status: cg21161138
(F = 9.48, P = 2.0 × 10-03) and cg25648203 (F = 7.72,
P = 6.0 × 10-03). This provides further support for aEthnic Group
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Figure 2 Plot showing interaction between ethnic group and
smoking at AHRR cg05575921. Bars show mean DNA methylation
levels in each group shown. Error bars represent standard deviations.
Ethnic differences were observed between current smokers
(t-test: n = 36, P = 2.0 × 10-3) but not between never smokers
(t-test: n = 129, P = 0.44).true interaction between ethnicity and smoking status at
this locus.
However, when repeating this analysis on AHRR
sentinel CpG site cg05575921 and adjusting for cell
composition this observation is attenuated (F = 6.08,
P = 1.5 × 10-2). This suggests that the interaction between
ethnicity and smoking that is mediated at least in part
through an effect on cell composition or the mechanisms
responsible for the change in cell composition at this locus.
Other sentinel CpG sites were also approaching
significance for interaction after adjustment for multiple
testing (see Additional file 2) and in all cases Europeans
showed larger effect sizes when comparing never and
current smokers (See Table 3).Ethnic differences-main effects
Following analyses for interactions, the main effects of eth-
nic group were also assessed. Main effects of ethnic group
existed in 2 of the 12 loci: 6p21.33 (cg06126421, n = 165,
F = 32.82, P = 4.9 × 10-8) and GNG12 (cg25189904, n = 165,
F = 17.94, P = 3.8 × 10-5). At both of these CpG sites methy-
lation differences were observed between never smokers of
the two ethnic groups (t-test: cg06126421; -8.71% in
Europeans, n = 129, t = −4.35, P-value = 2.8 × 10-5 and
cg25189904; -4.34% in Europeans, t = −3.08, P-value =
3.0 × 10-5). When repeating analysis on data adjusted
for cell composition, the main effect at 6p21.33 was
attenuated slightly (F = 10.96, P = 1.2 × 10-3) but the
main effect at GNG12 was not (F = 17.94, P = 3.8 × 10-5),
suggesting that differences in cell composition do not
wholly account for the differences observed at these loci.
This finding indicates that at some loci ethnic differences
exist independently of self-reported smoking status and
appear to be unrelated to cell composition. The source of
ethnic differences in methylation at these loci is unknown.
One potential source could be population specific local
mQTLs, such as described in previous studies [18,19],
causing underlying ethnic differences in DNA methylation
independently of smoking exposure. Another potential
source could be cultural or environmental factors not
captured in this study; for example, if a higher proportion
of European never-smokers have unmeasured passive
smoking exposure, this may have contributed to the
observed differences in methylation patterns. Variation
in diet between ethnic groups could also contribute
to the differences observed. In either case this highlights
the need for appropriate sample selection and accounting
for ethnic group in future studies.Using methylation scores to predict current smoking
status in Europeans and South Asians
Smoking scores were calculated for each SABRE individual
from whom methylation data had been measured (n = 189).
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distinct scores (see Figure 3a).
Random Forests were used to identify the threshold
score separating smokers and never smokers and to
assess misclassification. The average threshold score
separating the two groups using 500 trees was 17.55. This
threshold detected smokers from never and former smokers
with 100% sensitivity and 97% specificity.
In Europeans, the majority of former smokers had
scores <17.55 and were indistinguishable from never
smokers using this classification. This finding is in line with
published research observing that methylation levels in
former smokers revert to levels similar to never smokers
over time [3,7]. Smoking score was therefore not a good
identification tool for former smokers who, in the SABRE
cohort, had quit smoking for an average of 12.9 years.
Shenker and colleagues recently used bisulphite pyro-
sequencing data from four loci (AHRR, 6p21 and two
at 2q37) to differentiate between never and former
smokers, establishing that their method worked favourably
compared to cotinine measurement [8]. This suggests a
small subset of smoking associated loci where methylation
levels may be slower to revert to levels similar to never
smokers. If this is the case, methylation of these loci may
be useful for detection of former smoking behaviour.
Further comparison in larger numbers of former and
never smokers is needed to investigate this possibility.
Two former smokers had smoking scores very close to
current smoker levels. We hypothesise that these individ-
uals may still smoke or live in environments where they
are exposed to substantial amounts of passive smoke. This
finding underlines the need for an objective measure of
smoking status for precise classification in epidemiological
studies, to overcome misreporting bias.
In South Asians, current smoking behaviour was more
difficult to distinguish (Figure 3b). Random Forests wereFigure 3 Plots of smoking score by reported smoking category in Eur
interquartile ranges. Filled black circles show individual data points. Red lin
to be current smokers.used to identify the threshold score separating smokers
and never smokers. The average threshold score separating
the two groups using 500 trees was 11.79. This threshold
smoking score discriminated smokers from never and
former smokers with 80% sensitivity and 95% specificity.
Similarly to Europeans, former smokers had smoking
scores approaching those of never smokers.
Applying the European calculated threshold for current
smoking behaviour to the South Asian component of the
cohort would have altered sensitivity and specificity for
detection of current smoking in South Asians to 50% and
100%, respectively. Vice versa, sensitivity and specificity
would have been altered to 100% and 89%, respectively.
This highlights differences in methylation score profiles in
South Asians and Europeans and implies that smoking
score and smoking behaviour may be related.
Relationship between smoking score and smoking
behaviour
To assess whether a smoking score representing overall
methylation pattern was associated with smoking behaviour,
linear regression models were constructed.
When assessing the relationship between smoking score
and the number of cigarettes smoked per day, there was
an interaction between number of cigarettes smoked
per day and ethnic group (P = 3.38 × 10-3). Similarly,
an interaction between pack years and ethnic group
was also identified (P = 1.18 × 10-2). For this reason, the
relationships between these smoking behaviours and
smoking score were stratified by ethnic group.
In South Asians, a one unit increase in smoking score
was associated with a 0.54 increase in number of cigarettes
smoked per day (95% CI: 0.15, 0.93; P = 0.01), see Figure 4a.
A one unit increase in score was weakly associated
with a 0.29 increase in pack years (95% CI: 0.002,
0.571, P = 0.048), see Figure 4b. In Europeans, smokingopeans and South Asians. Box and whisker plots show median and
e indicates threshold score above which individuals were considered
Figure 4 Plots of associations between smoking score and smoking behaviour in Europeans and South Asians. Filled circles show
individual data points coloured by ethnic group (black = European, red = South Asian). R-squared values given are for regression models predicting
smoking behaviour using smoking score in each ethnic group.
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smoked per day or pack years. One reason smoking score
was not related to smoking behaviour measures in SABRE
Europeans is because scores amongst SABRE Europeans
were far more homogeneous than their South Asian
counterparts and we were therefore underpowered to
detect such associations (see Figures 4a, b).
Smoking score was not associated with years since
quitting (former smokers) or age at which smoking
began (current smokers) after adjusting for ethnic
group and no interaction between smoking behaviour
(years since quitting or age at which smoking began)
and ethnic group was observed.
The threshold score used to categorise current smoking
in South Asians was much lower than for Europeans. The
association between smoking score and measures of
smoking behaviour in South Asians adds support to the
hypothesis that differences in smoking effects are likely to
be attributable to the lighter use of cigarettes amongst
South Asian smokers. This finding is of interest to other
cohorts who may wish to use methylation smoking score
to categorise current smokers.
Conclusions
DNA methylation loci responsive to smoking were similar
in South Asians and Europeans, but for some loci the
degree of methylation differed markedly. Methylation
at the AHRR locus is significantly lower in European
origin individuals than South Asians. Although Europeans
reported heavier smoking than South Asians and part ofthe differences observed appeared to be related to
differences in cell composition, these factors could not
completely account for their lower scores, suggesting that
either key aspects of smoking behaviour had not been
captured, or that there is a true ethnic difference in
methylation response to smoking.
Ethnic differences in non-smokers at two smoking asso-
ciated loci were identified (cg06126421 and cg25189904),
where differences in methylation occurred between current
and never smokers. Differences observed between ethnic
groups in never smokers highlights differences not
attributable to smoking and could be driven by underlying
genetic variation or could be associated with other
un-captured environmental differences. This finding
indicates the need to take account of ethnic origin in
future research in this area.
Adjustment of methylation data for cell composition
using a method constructed by Houseman et al. allowed
the impact of cellular composition within the collected
samples to be assessed. It was noted that a subset of loci
associated with smoking may arise from differences in
cell composition between smokers and never smokers.
We also identified that an ethnic specific smoking
score derived from smoking related methylation profiles
is a valid marker for current tobacco exposure in both
South Asians and Europeans, offering a precise measure
of smoking status that is not prone to reporting bias,
and, therefore, of considerable value when attempting to
dissect the true association between smoking and smoking
related outcomes.
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Cohort information
SABRE is a population based cohort including 1,711 first
generation South Asian migrants and 1,762 people of
European origin aged 40 to 69 living in West London, UK
[20]. Baseline investigations were performed between 1988
and 1991. Peripheral blood samples were collected at
baseline visits for DNA extraction.
The current analysis was restricted to men only
(as previous studies have reported sex differences in
smoking associated methylation signals, and few South
Asian women smoked), and excluded all those with
existing chronic disease, specifically cardiovascular
disease and diabetes, restricted to those aged 40 to 55
years at baseline to avoid the confounding effects of
ageing on methylation patterns and to those who provided
good quality DNA samples. A random sample of 192 men
were selected, stratified by ethnicity, four-year age group,
and smoking status (current, former or never).
Ethnicity in the SABRE cohort was interviewer-recorded
based on parental origins and appearance and was
subsequently confirmed by participants. Half of the
samples selected in the current study were of European
origin born in mainland UK (England n = 89; Wales n = 3;
Scotland n = 4). The remaining participants were of South
Asian origin who indicated their region of origin was
North India (n = 92) or Pakistan (n = 4). Smoking status
was recorded by questionnaire. Participants reported the
age at which they began smoking and the year they
stopped if they had quit. The number of cigarettes smoked
per day was also recorded which allowed pack years of
smoking to be calculated using the formula: (cigarettes
per day/20) * number of years smoked.
All participants gave written informed consent. Approval
for the baseline study was obtained from Ealing, Hounslow
and Spelthorne, Parkside, and University College London
research ethics committees.
HumanMethylation450 BeadChip arrays
Genomic DNA (500 ng) was bisulphite modified using an
EZ DNA methylation kit (Zymo Research, Orange, CA,
USA). The protocol was as described by the manufacturer,
utilising the alternative incubation conditions recom-
mended when using Illumina Infinium Methylation
Arrays. Genome-wide methylation was measured using the
Illumina HumanMethylation450 BeadChip (Illumina, San
Diego, CA, USA) following the manufacturer’s protocol
with no modifications. The arrays were scanned using an
Illumina iScan with software version 3.3.28.
Pre-processing of methylation data Initial quality con-
trol of sample data was conducted using GenomeStudio
version 2011.1 (Illumina, San Diego, CA, USA) to deter-
mine the status of staining, extension, hybridisation, targetremoval, bisulphite conversion, specificity, non-polymorphic
and negative controls. Samples that did not pass this
stage of quality control were excluded from further
analysis (n = 3).
Data were pre-processed using the pipeline described in
Touleimat and Tost [21], with additional modifications
[21]. All probes were represented by more than three
beads and all samples contained >95% of signals that were
detectable from background signal (probe signal detection
P-value <0.01). In addition to these quality control steps
implemented by the pipeline, probes that contained <95%
of signals detectable above background signal (detection
P-value <0.01) (n = 9,769) and probes with multiple
homology (n = 25,083) (see Additional file 3) were excluded.
Following pre-processing, the percentage of methylation
present in the cell population at any given methylation site
is reported as a β-value. This is a continuous value
bounded by 0 and 1 which corresponds to the ratio of the
methylated signal divided by the sum of the methylated
and unmethylated signals. In statistical models, β-values
were transformed using a variance stabilisation trans-
formation to methylation M-values [22]. A second dataset
was also generated containing data further adjusted for
differences in cell composition, achieved utilising the
method described by Houseman et al. [23]. This allowed
the effect of cell composition to be evaluated. Prior
to implementation of statistical models, M-values were
adjusted to remove batch effects using ComBat [24],
where each BeadChip was considered to be one batch.
ComBat was not utilised in data used to generate scores.
For ease of interpretation, data shown throughout are in
the form of methylation β-values.
Using methylation scores to predict smoking status in
Europeans and South Asians
Weights and reference data used to calculate scores utilised
data published by Zeilinger et al. [7]. Use of data from a
second cohort minimised over-fitting. Data from this paper
were used as it is currently the most comprehensive list of
validated smoking associated CpG sites.
Weighted methylation scores were calculated utilising
data from 183 CpG sites previously associated with smoking
[7]. Three additional CpG sites reported by Zeilinger et al.
did not pass quality control measures in the SABRE cohort.
Calculating weights Effect sizes from discovery and
replication cohorts were taken from supplementary
Table 2, published by Zeilinger et al. [7]. Weights were
calculated as absolute values: per CpG effect size/average
effect size for all measured CpG sites.
Calculating scores Median methylation values of
never smokers taken from previously reported data
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as above [7]).
Smoking scores were first calculated for each CpG site.
For CpG sites associated with increased methylation
levels in smokers, smoking scores were calculated as:
(SABRE cohort beta values – reference beta values)
*weight. For CpG sites associated with decreased methyla-
tion levels in smokers, smoking scores were calculated as:
(reference beta values – cohort beta values)*weight. The
final weighted score was calculated as the sum of all CpG
site scores.
Analysis
Baseline characteristics comparing South Asians and
Europeans were compared using the t-test for continuous,
and chi-squared for categorical variables. ANOVA was
used to identify associations between methylation and
smoking status in smokers and never smokers, where
methylation M-values were the outcome variables,
smoking category represented the predictor variable
and ethnic group was included as a covariate. To determine
whether there were ethnic differences in the association
between smoking and methylation score we included an
interaction term smoking status * ethnic group in the
model. Linear regression models were used to assess
associations between methylation and smoking behaviours
and between smoking score and smoking behaviours.
Estimated power to detect 5% methylation difference
between smokers and never smokers assuming a conserva-
tive standard deviation estimate of 4% in each group
and n = 165 (36 current and 65 never smokers) was
90.72% at P = 1.1 × 10-7.
All analyses were conducted in R, version 3.0.0
(http://www.r-project.org). The following packages were
utilised: base, stats, lumi methylumi, CpGassoc, sva and
RandomForest [25-29].
Additional files
Additional file 1: A table listing summary and test statistics for all
CpG sites associated with smoking in SABRE.
Additional file 2: A table listing test statistics for interaction analyses.
Additional file 3: A table listing CpG probes with multiple homology.
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